

FOR IMMEDIATE RELEASE

Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY[®] (donepezil transdermal system) for the Treatment of Alzheimer's Disease

MENLO PARK, Calif., January 27, 2020 (GLOBE NEWSWIRE) – Corium, Inc., a commercial

About Alzheimer's Disease

Alzheimer's disease is a progressive brain disorder in which brain cells degenerate and die, causing a steady decline in memory and mental function. According to the Alzheimer's Association, an estimated 5.8 million Americans were living with Alzheimer's disease in 2019; by 2050, this number is projected to rise to 13.8 million. Alzheimer's disease is the most common cause of dementia among older adults. Dementia ranges in severity from mild, when it is just beginning to affect a person's functioning, to moderate, and severe, when the person must depend on others for the basic activities of day-to-day life.

About Corium

Corium, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners including Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex for small molecules and MicroCor[®], a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In November 2018, all of Corium's outstanding stock was acquired by an affiliate of Gurnet Point Capital. For further information, please visit www.coriumintl.com.

About Gurnet Point Capital

Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Chris Viehbacher, who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of \$2 billion, GPC is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge, MA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialization and does so with an approach that is a hybrid of venture and private equity investing strategies. www.gurnetpointcapital.com

ADLARITY[®], Corplex[™] and MicroCor[®] are registered trademarks of Corium, Inc.
Aricept[®] is a registered trademark of Eisai Inc.

###

Contact:
Corium, Inc.
Christina Dickerson
christina@coriumtech.com
(650) 298-8257